Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021. Skip to main content. Skip to main menu; Skip to user menu; Login |It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -2.84%). Earlier this year, the company's shares skyrocketed after it announced a partnership with the ...The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8.While the stock dipped to about $8.58 following that note, there’s still a lot to like here ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Today, we take our first look at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead?SALT LAKE CITY, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...Chief Business Officer (Nasdaq: RXRX). Recursion University of Cambridge. St Petersburg, Florida, United States. 3K followers 500+ connections. See your mutual ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Instantly RXRX has showed a red trend with a performance of -4.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.23 on Monday, 11/27/23 increased the stock’s daily price by 9.68%.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at 5:37 AMRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Founded in 2013, Recursion Pharmaceuticals is a Utah-based clinical stage "digital biotech", possessing a sophisticated robotized biology experimentation drug discovery platform, utilizing machine learning technologies, including high-throughput imaging analytics and high content …Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings.Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksRecursion Pharmaceuticals (NASDAQ:RXRX) recently gapped higher after receiving a $50 million investment from AI powerhouse Nvidia (NASDAQ:NVDA).With that, Recursion will use NVDA technology to ...Nov 18, 2023 · Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ... Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ...That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention.Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...Recursion Pharmaceuticals Inc (NASDAQ:RXRX). 7.38. Delayed Data. As of Dec 01. +0.53 / +7.74%. Today's Change. 4.54. Today|||52-Week Range. 16.75. -4.28%. Year- ...Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart. Buy RXRX stock at Webull.Recursion Pharmaceuticals Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for RXRX in the last 3 months.Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Find the latest dividend history for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Yet, risky stocks can also often offer attractive upside potential. Let's look at two examples: Recursion Pharmaceuticals ( RXRX 4.40%) and Madrigal Pharmaceuticals ( MDGL 1.83%). These two ...12 Nis 2023 ... investments in companies including Recursion (NASDAQ: RXRX), which uses automation and deep learning to develop novel therapeutics; Enveda ...Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year.Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...SALT LAKE CITY, June 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the full ...Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.View the latest Nasdaq Inc. (NDAQ) stock price, news, historical charts, analyst ratings and financial information from WSJ.2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) …Find the latest quotes for Vanguard S&P 500 ETF (VOO) as well as ETF details, charts and news at Nasdaq.com.Stock Recursion Pharmaceuticals, Inc. - Nasdaq. Recursion Pharmaceuticals, Inc. (RXRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and …Pre-Market Quotes Nasdaq-100 Ownership Search News + Insights Solutions Recursion Pharmaceuticals, Inc. Class A Common Stock P/E & PEG Ratios …Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES.SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.NVIDIA Corporation Common Stock. $450.47 +0.42 +0.09%. MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ...12 Tem 2023 ... SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company ...Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...SALT LAKE CITY, June 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio biotechnology company. It is focused on utilizing advanced technologies in biology, chemistry, …View real-time RXRX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Jul 13, 2023 · Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. #3 Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) Sector: Healthcare | Biotechnology. Reason: Falling Wedge Pattern Breakout. A falling wedge pattern is formed by joining two downward-sloping, converging trendlines having a contracting range. The pattern appears to be wide at the top and continues to contract as prices fall.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. In a notable insider transaction, Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023.NASDAQ:RXRX. Stock Report. RXRX. Recursion Pharmaceuticals. Stock Analysis. Analyst Forecasts. ... RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63 ...DocuSign (NASDAQ: DOCU) ... SDGR), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Amongst these choices, I would favor AbCellera Biologics in the current environment, ...According to the issued ratings of 4 analysts in the last year, the consensus rating for Recursion Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for RXRX. The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of …Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: ... (NASDAQ:RXRX) 908 Devices Inc (NASDAQ:MASS) 1life Healthcare Inc (NASDAQ:ONEM)About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a ...Check out our RXRX stock analysis, current RXRX quote, charts, and historical prices for Recursion Pharmaceuticals Inc Cl A stock. ... (NASDAQ:RXRX) From Seeking Alpha Oct 19, 2023 Royalty ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …Nov 30, 2023 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...Jul 6, 2023 · Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares. A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at …The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8.While the stock dipped to about $8.58 following that note, there’s still a lot to like here ...On October 11, 2023, Michael Secora, the Chief Financial Officer (CFO) of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 50,000 shares of the company.For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed...AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed...Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated Phase 2/3 POPLAR-NF2 trial of REC-2282 for progressive neurofibromatosis type 2-mutated meningiomas, tumors that form on the membrane that ...SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...Xerox Holdings Corporation Common Stock (XRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Recursion Pharmaceuticals (NASDAQ:RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...
Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now. However, its finances are nowhere near breakeven yet. NASDAQ: RXRX. Recursion Pharmaceuticals. Market Cap. $1B. Today's Change. (13.00%) $0.68.. Kia new sports car
Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...Dec 1, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at 5:37 AM Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Jan 12, 2022 · So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ... RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After …At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock ...Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Recursion Pharmaceuticals (NASDAQ:RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.9 Kas 2023 ... ... (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working ...13 Tem 2023 ... The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation;” and so on. But rather more ...On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock.Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia.But, since that month’s peak, RXRX’s stock ...Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the better stock?We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com..